AIDS Therapies (Ritonavir)
FDA Approves Second Protease Inhibitor To Treat HIV
Published in AIDS Weekly, March 18th, 1996
Ritonavir received full approval for use alone or in combination with nucleoside analogue medications, such as AZT, in people with advanced HIV disease. Ritonavir also received accelerated approval for less advanced HIV disease. FDA approved the drug about two months after receiving its application for its marketing.
"Even as we celebrate this milestone, we must recommit ourselves to President Clinton's goal of finding a cure," said HHS Secretary Donna E. Shalala. "We must also face the new challenge of providing life-prolonging medications to all...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
Source: AIDS Weekly (1996-03-18)
More Articles from AIDS Weekly
- Conference Coverage (NCVDG)
Experimental HIV Vaccine Recipient Became HIV Infected - Conference Coverage (NCVDG)
Gamma Interferon Gene Adds to Attenuation and Efficacy of Live Vaccine - Conference Coverage (NCVDG)
Live Attenuated SIV Vaccine Safe In Neonates At Normal Doses - Conference Coverage (NCVDG)
NIAID Announces AIDS Vaccine Prevention and Research Program (VPRP) - AIDS Therapies (Protease Inhibitors)
Committee Recommends Crixivan Protease Inhibitor for HIV - AIDS Therapies (Videx)
Committee Unanimously Recommends Approval of Videx - More from this issue of AIDS Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
